A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)

NCT03395210 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Immune Thrombocytopenia

Interventions

DRUG: Rilzabrutinib

Sponsor

Principia Biopharma, a Sanofi Company